XTAI
1720
Market cap350mUSD
Oct 08, Last price
56.90TWD
1D
1.43%
1Q
-10.95%
Jan 2017
74.54%
Name
Standard Chem & Pharm Co Ltd
Chart & performance
P/E
12.06
P/S
1.59
EPS
4.72
Div yield, %
4.92%
Shrs. gr., 5y
6.22%
Rev. gr., 5y
10.28%
Revenues
7.02b
+3.44%
Net income
928m
+5.36%
CFO
1.87b
+10.05%
Dividend
Jul 23, 20262.2 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Standard Chem & Pharm Co. Ltd. (SCP) is a Taiwanese enterprise specializing in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products, nutritional supplements, and Active Pharmaceutical Ingredients (APIs). The company's diverse offerings include medications targeting various therapeutic areas, such as the circulatory, digestive, and respiratory systems. Their portfolio also features antihistamines, central nervous system (CNS) agents, metabolism-regulating drugs, anti-microbial treatments, and topical preparations for skin and mucous membrane conditions. Beyond finished drug products, SCP provides APIs for both human and veterinary applications, as well as various pharmaceutical excipients. Founded in 1967, Standard Chem & Pharm Co. Ltd. maintains its corporate headquarters in Tainan City, Taiwan.
Key people
Chairman of the Board, General Manager · since 2023
Chin-Wen Chang
Chief Financial Officer, Head of Finance & Accounting, Corporate Governance Officer · since 2023
Wei-Ren Chen
Deputy General Manager · since 2001
Chin-Tsai Fan
Director · since 2023
Director · since 2012
Wen-Jang Lin
Deputy General Manager, Director · since 2023
Tsuey-Wen Yeh
Director · since 2021
C. Lee
Independent Director · since 2023
Shao-Zong Liu
Independent Director · since 2021
Hwei-Jiung Wang
Independent Director · since 2018
Yi-Zhen Zhang
Independent Director · since 2024
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||